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Abstract
Background: Schizophrenia is a severe and chronic medical condition, characterized by positive and negative
symptoms, as well as pervasive social cognitive deficits. Despite the functional significance of the social cognition
deficits affecting many aspects of daily living, such as social relationships, occupational status, and independent
living, there is still no effective treatment option for these deficits, which is applied as standard of care. To address
this need, we developed a novel, internet-based training program that targets social cognition deficits in schizophrenia
(SocialVille). Preliminary studies demonstrate the feasibility and initial efficacy of Socialville in schizophrenia patients
(Nahum et al., 2014). The purpose of the current trial (referred to as the TReatment of Social cognition in Schizophrenia
Trial or TRuSST) is to compare SocialVille to an active control training condition, include a larger sample of patients, and
assess both social cognitive functioning, and functional outcomes.
Methods/Design: We will employ a multi-site, longitudinal, blinded, randomized controlled trial (RCT) design with a
target sample of 128 patients with schizophrenia. Patients will perform, at their home or in clinic, 40 sessions
of either the SocialVille training program or an active control computer game condition. Each session will last
for 40–45 minutes/day, performed 3–5 days a week, over 10–12 weeks, totaling to 30 hours of training. Patients will
be assessed on a battery of social cognitive, social functioning and functional outcomes immediately before training,
mid-way through training (after 20 training sessions) and at the completion of the 40 training sessions.
Discussion: The strengths of this protocol are that it tests an innovative, internet-based treatment that targets
fundamental social cognitive deficits in schizophrenia, employs a highly sensitive and extensive battery of functional
outcome measures, and incorporates a large sample size in an RCT design.
Trial Registration: ClinicalTrials.gov NCT02246426Registered 16 September 2014
Keywords: Schizophrenia, Rehabilitation, Social cognition, Computer-based cognitive training, Clinical trial
Background
Schizophrenia is a severe, chronic mental illness that
affects more than two million individuals in the U.S. [1].
Individuals with schizophrenia have both positive and
negative symptoms, including hallucinations, delusions,
disorganized speech and behavior, alogia (poverty of
speech), affect flattening, and avolition (inability to initi-
ate and persist in goal-directed behaviors) [2]. These clin-
ical symptoms are often accompanied by severe cognitive
deficits, in speed of processing, attention, working mem-
ory, verbal and visual learning and memory, and executive
function [3]. Moreover, individuals with schizophrenia
often exhibit difficulties in social functioning, namely in
their ability to navigate through the social world, create
meaningful interactions, and correctly interpret relevant
social context [4]. This poor social functioning has been
attributable to pervasive and enduring impairments in
social cognition [5–10]: the perception, interpretation and
processing of socially-relevant information [11–16]. Indi-
viduals with schizophrenia exhibit deficits in all core
domains of social cognition [17, 18]: emotion perception
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(the recognition of facial and vocal affect) [19–23], social
cue perception (the ability to detect and comprehend cues
in a social context) [24–26], theory of mind (the mental
capacity to infer one’s own and others’ mental states)
[1, 27–29], attributional style (attribution of causes of
events to the self, to others, or to factors in the environ-
ment) [30, 31], and empathy (the ability to share, under-
stand and appropriately react to the emotional states of
others) [32]. Recent studies have shown that these social
cognitive deficits in schizophrenia are rooted in anatom-
ical and functional abnormalities within a complex brain
network collectively termed “the social brain” [33–39],
and include the superior temporal sulcus (STS), anterior
insula, amygdala, medial prefrontal cortex (mPFC), and to
the cingulate cortex [40–44]. These fundamental, multi-
domain social cognition impairments are not only directly
linked with poor social functioning, but also underlie most
critical factors of daily living in schizophrenia, such as low
occupational status, poor social and community func-
tioning, reduced capabilities for independent living, high
relapse rate, and reduced quality of life [2, 4, 45–51].
Moreover, the degree of social cognition impairment is
a stronger predictor of the level of everyday functional
ability than are cognitive abilities or the severity of positive
symptoms [52, 53]. This makes social cognition an im-
portant treatment target in schizophrenia: as the ultimate
goal of therapeutic interventions is to improve life out-
comes for patients, it is now clear that recovery of these
individuals to the broader society is crucially dependent
upon the recovery of their social cognitive abilities. The
fact that social cognition deficits persist throughout the
course of the illness [22, 54, 55], are seen in prodromal pa-
tients [22], and are even present in unaffected relatives of
patients, further stresses their central role in schizophre-
nia and fuels the need for an effective, scalable treatment
for social cognitive deficits (see recent review in [44]).
Despite the importance of social cognition as a primary
source of impairment, there are currently no well-accepted
or even broadly administered treatment methods for im-
proving social cognitive function in schizophrenia patients.
Social cognitive deficits are resistant to pharmacological
treatments including second-generation antipsychotic
medications [56–60] that are effective for controlling
positive symptom levels [58]. Perhaps more surprisingly,
new and demonstrably effective interventions for treating
cognitive deficits in schizophrenia have been shown to
have only limited impacts on social functioning [61] -
presumably because social cognition deficits are associ-
ated with impaired function of neural networks that are
largely distinct from, and parallel to, those subserving
general neurocognition [18].
Several experimental, therapist-delivered approaches tar-
geting social skills or social cognition have been developed
over the last decade (e.g. [62–66]), and initial studies have
shown some promising results (see recent reviews in
[52, 67, 68]). These interventions are offered in only a
few clinics nationwide and are usually administered by
trained professionals individually or in small groups over
the course of several months. The therapist-administered
options (e.g. Social Cognition and Interaction Training
(SCIT) [66, 69–71]; Social Cognitive Skills Training (SCST)
[72]; Emotion and ToM Imitation Training (ETIT) [73];
Social Cognition Enhancement Training (SCET) [74])
usually focus on emotion management and social skills
building, and require multiple in-person visits to the
clinic in the course of a few months. Recently, several
computer-aided interventions (e.g. Tackling Affect Recog-
nition (TAR) [75]; MicroExpression Training Tool (METT)
[65]) have been created. These interventions are limited in
scope (mainly target a single social cognitive domain in iso-
lation, such as facial affect recognition), have undergone
only initial testing in schizophrenia [52, 65, 75], and are
not used, to the best of our knowledge, in any clinical treat-
ment programs. While, collectively, these approaches show
promise for social cognitive treatment in schizophrenia, to
date, no single treatment has been widely adopted, and
there is no standard of care for social cognitive treatment
in schizophrenia. This is potentially due to the fact that
these interventions are not scalable and cost-effective, as
they require highly-trained personnel and necessitate fre-
quent visits to the clinic, limiting their scalability and sig-
nificantly increasing their associated costs.
To address the need for a scalable and effective treat-
ment for social cognition deficits in schizophrenia, that
considers these deficits from their neurological core (see
[44, 76, 77] for recent reviews on this topic), we have de-
veloped SocialVille, an internet-based treatment program
designed to specifically address the core social cognitive
domains of deficit in individuals with schizophrenia. While
the use of computer-based strategies to strengthen social
behaviors may seem paradoxical or counter-intuitive, the
goal of this form of training does not entail strengthening
explicit social skills, but rather strengthening the brain
basis that comprises these skills, for which the use of a
computer is a substantial advantage. The 27 different exer-
cises of SocialVille collectively encompass the five social
cognitive domains (see Table 1 for a complete list). The
user is required to make hundreds of speeded, accurate,
and increasingly more challenging discriminations of
socially-relevant information (e.g., emotional faces, eye
gazes, prosody, social situations). During training, the user
is systematically exposed to socially-relevant stimuli, start-
ing from very basic-level stimuli and gradually involving
more complex, multi-modal, and ecologically-valid stimuli.
Trial-by-trial difficulty is adaptively set using either up-
down [78] or Bayesian [79] algorithms, maintaining
individual success rate at 70-80 % success level, allowing
for progression through training based on the user’s
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individual performance level. Finally, a secure online
clinician portal allows the treating clinician to track user
performance and treatment compliance.
Two recently-published studies using SocialVille show
promising initial results in both adults with schizophrenia
[80] and in young adults at high clinical risk for psychosis
[81]. Nahum et al. found that following 24 hours of Social-
Ville training, participants showed improvements in prox-
imal measures of social cognition (e.g. facial memory,
prosody identification), as well as in more remote mea-
sures of social functioning and motivation [80]. These pre-
liminary results of SocialVille demonstrate some transfer
of training benefits to more general skills. The current
multi-site clinical trial extends this and other studies with
a longer duration of SocialVille training (30 hours total),
the inclusion of an active control training condition (com-
puter games, see Table 2), and the inclusion of additional
social and functional outcome measures.
Two additional innovations in the current protocol are
worth mentioning. First, to the best of our knowledge, this
trial is the first to include a fully-Internet-based treatment
for social cognitive deficits in schizophrenia, designed to
be completed entirely remotely (from home), with min-
imal supervision and clinic visits only for assessments
(see recent review of training studies in [82]). Some stud-
ies employing social cognition training in schizophrenia
have used computerized interventions, but these were
usually applied as part of a larger, instruction-based ther-
apy [66, 69–72, 83] or in small groups of participants in
the clinic (e.g. [84]). The advantage of using a fully online
training program is that it can be adaptively tailored to pa-
tient’s individual abilities to provide the appropriate level
of training, and is easily scalable to support many users.
The second innovation in our current protocol is the
use of a large battery of outcome measures, including novel,
computerized measures (e.g. Virtual Reality Functional
Capacity Assessment Tool (VRFCAT) [85]). As the ultim-
ate goal of clinical intervention is to improve functional
outcomes by improving social abilities, it is important to
document the degree of improvement in various aspects,
encompassing social and global functioning, quality of
life, functional capacity, motivation, and symptom
severity level. Nonetheless, previous studies generally
employed limited batteries of outcome measures (see [67,
68]) or lacked adequate controls that are matched for
intensity and experimenter contact [86].
Table 1 SocialVille training exercise
Exercise Description
Affect Perception
Name That Feeling Select the label which correctly describes
the target facial affect (stills)
Face It Identify the target face within a group of faces
Match that Feeling Match the facial affect of the target face
with that of an array of different faces
Voice Choice Select the label which correctly describes
the target vocal affect (prosody)
Second That Emotion Match pairs of cards that express the same
facial affect
Second That
Intonation
Match pairs of cards that express the same
vocal affect (prosody)
Emotion Motion Select the label which correctly describes
the target facial affect (video clips)
Emotion
Motion:Flashback
Memorize a sequence of facial expressions
(video clips)
Social Cue Perception
Recognition Select the target face from an array of
neural faces
Face It: Flashback Memorize a sequence of faces
Gaze Cast Follow the gaze shift of a person, to track
the peripheral object looked at
Gaze Match Select the target gaze from an array of
gazes (irrespective of face identity)
Life Stories Answer questions regarding social cues
after listening to a segmented story
Face Facts Memorize visually-presented social facts
about individuals presented serially
In the Know Memorize aurally-presented social facts
about individuals
Face and Name Memorize pairs of faces and names
Pragmatic Ambiguity Determine if the given conversation
makes sense (visual scene)
Social Skills Choose the best way to respond during
a difficult conversation
Self-Referential Style
Mass Affect Memorize internally-generated valence
labels over time
Bright Whites Identify which of two people displayed the
more positive affect
Grin Hunting Select the more positive scene to detect
smiles in a subsequent image
Theory of Mind
Social Scenes Rate the likehood of people’s reactions
and feelings in social situations
What Joe’s Thinking? Track a person’s gaze shift to determine if they
are looking at the same object as the person in
their line of view
What Happened? Determine the most likely scenario given
the least amount of hints
Say What? Decide how would a person would respond in a
given situation (audio scene)
Table 1 SocialVille training exercise (Continued)
Person Description Infer what someone believes based on
given facts about them.
Empathy
Multi-person
Perspective-Taking
Decide how a person will be affected by
a given situation (visual scene)
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Aims and hypotheses
The aim of the current study is to test the effectiveness of
30 hours of computer-based SocialVille training to improve
social cognition and functional outcome in schizophrenia,
compared with an active control intervention. Based on
our previous findings, we predict that the SocialVille group
will show statistically greater gains on co-primary outcome
measures of social cognitive performance and functional
performance as well as secondary measures of social cogni-
tion, functional capacity, functional outcome, motivation,
and quality of life, indicating that SocialVille drives general-
ized social cognitive improvements as well as real-world
functional improvements. Secondary aims include deter-
mining which patients best respond to SocialVille, and
evaluating the effects of SocialVille training on low-level vs.
high-level social cognition factors. For treatment response,
we will examine predictors of social cognitive gains based
on baseline participant demographic, symptom severity
level, prior computer use, and functional measures, as well
as on learning rate and plateau performance measures
derived over the course of SocialVille use. Based on our
previous studies, we hypothesize that most baseline mea-
sures will not define responder/non-responder groups
effectively (except potentially for symptom severity), while
baseline exercise performance, learning rate and plateau
performance during SocialVille use will predict overall
gains. Finally, we will separately examine the effects of
training on the independent social cognitive factors of
low-level social cue detection and high-level inferential
process. We hypothesize that both low-level and high-
level social cognition factors will be significantly correlated
with functional capacity and real-world social and role
functioning.
Methods
Ethics Statement
The Western International Review Board (WIRB) is
designated to review and provide continuing oversight of
ethical standards involving human subjects research
(WIRB Pro Number 20141695). Research is conducted in
accordance with the Declaration of Helsinki and moni-
tored by the WIRB. Participants interested in the study
will meet with qualified study staff for the consenting
process, during which the participant is informed of the
nature of the trial, purpose of research, trial procedures,
risks and benefits, confidentiality, etc. Following consent,
the participant will be assessed for eligibility and potential
enrollment in the trial. Minors are excluded from this
study and will not undergo the consenting process.
Overall Design and Timeline
The current study will employ a multi-site, longitudinal,
blinded randomized controlled trial (RCT) design with a
target sample of 128 patients with schizophrenia (see
inclusion criteria below). This trial will follow the Con-
solidated Standards of Reporting Trials (CONSORT) guide-
lines [87] for the design, execution, and reporting of
clinical trials, with the Non-Pharmacologic Treatment
Interventions extensions to reflect the use of computerized
social cognitive remediation as a treatment intervention.
Sixty-four patients with schizophrenia completing
SocialVille will be compared to sixty-four patients with
Table 2 Active cotrol training games
Game Description
Chinese Checkers Move your pieces to the opponent’s end by moving or jumping over pieces
Sudoko Fill each square in the puzzle with a number (1-9) given rules
Reversi Try to have the majority of the disks on the game present your color
Double Klondike Solitaire Participants must stacks cards alternating in color in descending order with the goal of forming complete
A-K stacks of the same suit.
Tri Peaks Solitaire The object of the game is to remove all cards that make up the “three peaks.” Player must stack the cards
present on the ‘peaks’ to the card on the bottom
Brick Breaking Hex Click on a group of blocks with the same color. To remove individual blocks, you lose one of your stars.
The goal is to get rid of all the blocks before you lose all your stars
Brick Squasher II Use the mouse to control the board to bounce the balls and destroy the bricks. Some bricks require a few
hits and some bricks are indestructible
Gem Swap Swap adjacent gems to create 3 or more in a row to remove the gems
War Ship Hide your ships then take turns with the computer player to search for the opponent’s hidden ship.
The object of the game is to find your opponent’s ships and sink them before they find yours
A Maze Race There are two balls, the green one is designated to the participant and the red is the computer player.
The participant must find the ‘Flag’ or end point before the computer does
Lineup 4 Participant and computer player take turns dropping discs from the top into a grid. The player must connect
four yellow discs in a row (vertically, horizontally or diagonally) before the opponent
Word Search Letters are placed in a grid and the participant must find the specified list of words hidden within the grid
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schizophrenia completing the active control condition
(online computer-based games; see Fig. 1). Total participa-
tion time is approximately 12–14 weeks and includes
seven (7) in-person assessment sessions. The first assess-
ment session (V0) involves screening for eligibility (see
inclusion/exclusion below). If the participant is eligible,
they next perform two baseline assessment visit (V1-V2) to
provide baseline level of their symptoms, social cognition,
social functioning, functional capacity and motivation
before training. After the baseline assessments, patients are
randomized to either the SocialVille or control training
program, and complete a set-up visit (V3) in which they
are provided with a study laptop with their corresponding
training program. Participants are then requested to
complete 40 training sessions (about 10–12 weeks) of
in-home training, while monitored remotely by a research
assistant (cognitive remediation coach). Participants will
be assessed again at the completion of 20 sessions (mid-
intervention assessments; V4-V5) and at the completion
of the entire training of 40 sessions (post-intervention
assessments, V6-V7), to measure potential training-
related improvements. After this visit (V7), participant
activities are completed and trial participation ends.
All assessments will be done by assessors that are blind
to group affiliation.
Study Population
The study population is comprised of individuals diag-
nosed with schizophrenia. All participants must be clin-
ically stable and be stable on the doses of the psychiatric
medications they are taking. For the purposes of this
trial, we will focus on treating core symptoms rather than
examining etiology, and only enroll those individuals that
meet inclusion/exclusion criteria (see below).
We will employ a multi-site study, which is used to en-
sure that the results are not particular to the participant
population or study operations at a single site. We have on-
going research collaborations with all site PIs (who served
as consultants and collaborators on the Phase I grant).
Study participants will be recruited with established and
proven mechanisms developed at each site. All Site PIs,
internationally-recognized experts in the field, have exten-
sive expertise in this population as well as access to large
cohorts of patients with schizophrenia.
We do not anticipate any specific barriers to the ac-
crual of participants, nor are we aware of a large number
of competing clinical trials that would limit enrollment.
The study population is limited to those 18 years of age
or older. We chose a minimum age of 18, to match the
minimum age for participation without parental consent,
and since schizophrenia is usually seen in adults above
Fig. 1 Study Outline. Following screening and baseline visits, participants are randomized into the experimental intervention (SocialVille) or the
active control intervention (AC), in which they complete 40 sessions of training, with assessment visits conducted after 20 sessions and after
training completion
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this age. The study is open to all races, ethnicities,
and genders. Selection of participants is based on psy-
chiatric condition and is not based on gender or
ethnic considerations, although these are expected to
reflect the diverse population of San Francisco Bay
Area, Los Angeles, and Boston. Ethnic minorities will
be included when available and recruiting efforts will
target a balanced enrollment.
The following inclusion/exclusion criteria will be
determined through our screening procedures during
V0, which includes structured interviews, as well as
computerized and standardized neuropsychological as-
sessments of attention, cognition and functional abilities.
Inclusion Criteria
1. Subjects must be between 18 and 65 years old at the
time of study screening
2. Subjects must have a diagnosis of schizophrenia as
defined by DSM-V criteria and confirmed by the
Structured Clinical Interview for DSM-IV (SCID-P
[88]). The SCID-P is a semi-structured clinical
interview used to determine major mental disorders
and personality disorders and will be used to confirm
diagnosis of schizophrenia.
3. Subjects must demonstrate adequate decisional
capacity, in the judgment of the consenting study
staff member, to make a choice about participating
in this research study.
4. Subjects must have been clinically stable (non-acute)
for 8 weeks prior to consent; in the judgment of the
Site Principal Investigator.
5. Subjects must have been maintained on a stable
treatment of antipsychotics and/or other concomitant
psychotropic treatment for at least 6 weeks prior to
consent.
6. Subjects must have learned English before the age
of 12 to ensure valid neuropsychological results.
7. Subjects must have the visual, auditory, and motor
capacity to use the computerized intervention in
the judgment of the consenting study staff person.
8. Subjects must have no more than a moderate
severity rating on hallucinations and unusual
thought content as shown by a score of ≤ 4 on the
Positive and Negative Symptoms Scale (PANSS [89]).
Exclusion criteria
1. Subjects should not have had a psychiatric
hospitalization in the 8 weeks prior to consent.
2. Subjects who appear to be intoxicated or under the
influence of a controlled substance on any day of
assessment must be rescheduled or discontinued
based upon the discretion of the site staff evaluator.
3. Subjects should not have a history of mental
retardation (IQ < 70 based on The Wechsler
Test of Adult Reading, WTAR [90]) or pervasive
developmental disorder; or other neurological
disorder (e.g., Traumatic Brain Injury, epilepsy,
Parkinson’s Disease)
4. Subjects should not have been treated within 5 years
of the date of consent with a computer-based cognitive
training program manufactured by Posit Science.
5. Subjects should not be participating in a concurrent
clinical trial that, in the judgment of the Site Principal
Investigator, could affect the outcome of this one.
6. Subjects should not be prescribed more than two
anti-psychotics. Subjects should not be treated with
medication(s) with a total Cogentin equivalent greater
than 4.5 mg (known anti-cholinergic side effects)
7. Subjects who have answered ‘yes’ to Question 5
(Active Suicidal Ideation with Specific Plan and Intent)
on the Columbia-Suicide Severity Rating Scale
(C-SSRS [91]), or who have answered ‘yes’ to any
of the suicide-related behaviors (actual attempt,
interrupted attempt, aborted attempt, preparatory
act or behavior) on the C-SSRS “Suicidal Behavior”
portion shall be excluded from the study if ideation
or behavior occurred within two months of consent.
Subjects excluded for this reason will be referred for
appropriate treatment.
Repeated Assessment Battery (Outcome Measures)
Once a participant is deemed eligible for participation
based on their V0 results, they are next scheduled for
their baseline sessions on the repeated assessment bat-
tery (V1-V2), which take approximately four hours total.
After completing these baseline assessments, participants
are randomly assigned to either experimental or control
training conditions (see below). Then, after half of the
training is completed (20 sessions), participants are given
the repeated assessment battery (V4-V5), and again at the
completion of the entire training protocol (20 additional
sessions for a total of 40 sessions; V6-V7).
We will employ a battery of neuropsychological and
functional assessments (see Table 3), measuring a range
of parameters from proximal to very distal from program
use (e.g., assessment of functional abilities and quality of
life). This structure will allow us to determine the degree
of transfer of benefit to untrained modalities, including
the extent to which improvements generalize to untrained
functional ability and real-world experience (e.g., quality
of life). Assessments will be administered to all partici-
pants, including those enrolled in treatment and active
control groups; alternate forms of the assessments will be
used when available to mitigate test-retest effects. Site psy-
chometricians conducting the assessments will be blinded
to group allocation and will receive training by a member
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of the coordinating center staff regarding appropriate
administration of all measures, scoring and data reporting
to ensure data quality. Performance on all measures will
be scored, submitted by the participating site into the
study database, and monitored for accuracy and integrity
by the Coordinating Center.
Primary Outcome Measures
The FDA has indicated through the MATRICS (Measure-
ment and Treatment Research to Improve Cognition in
Schizophrenia) guidelines that it requires two co-primary
endpoints for trials of cognitive enhancement in schizo-
phrenia, a cognitive endpoint and a functional endpoint.
We will follow these recommendations and include two
co-primary outcome measures, a social cognitive outcome
measure and a functional capacity measure. Our selections
also adhere to the NIH toolbox recommendations regard-
ing assessments, as this trial is sponsored by the National
Institute of Mental Health (NIMH).
Social Cognitive Outcome Measure
The a priori co-primary social cognitive outcome measure
will be a composite score comprised of a standardized,
validated set of assessments that tap into low-level and
high-level SC (social cognition) abilities (see [92]). A com-
posite score will be derived from all five assessments to
provide a social cognitive co-primary measure which en-
compasses several SC abilities. All assessments have been
validated and used in outcome studies [68].
The low-level social cognitive assessments are:
1. ER40 (The Penn Emotional Recognition Test)[93] is
a computerized test to assess categorical identification
of facial emotions. The tasks consists of 40 digital
pictures of faces. The photos are presented
individually and subjects are required to choose the
most appropriate emotion label from five possible
emotion choices (happiness, sadness, anger, fear, or no
emotion). The 40 photos are of 8 actors, and there are
8 photos of neutral expressions, 4 low intensity and 4
high intensity photos for each emotion. The index of
accuracy is the total number of correct items and
response time. This measure was found to exhibit
70% accuracy of identifying emotions, with
concurrent validity of .83, convergent validity of .79
and divergent validity of .09.
2. PROID (Prosody Identification)[94] is a
computerized vocal identification task used to assess
a subject’s ability to perceive and discriminate
emotion in the speech of others. All stimuli have
been validated through trials with healthy controls.
3. PFMT (Penn Faces Memory Test)[93] consists of
20 target faces and 40 foil faces; Stimuli are black
and white photographs of faces, balanced for
gender and age. All faces are of neutral expression.
Participants are requested to view the pictures,
and are then tested immediately and after a delay
on the pictures they have seen, to determine if they
were in the set they memorized or not.
The high-level social cognitive measures are:
1. MSCEIT (Mayer-Salovey-Caruso Emotional
Intelligence Test)[95] managing emotions subscale
has two subtests that assess how participants
manage the emotions of others (Social Management)
and how a person would regulate his or her own
emotions (Emotion Management). The test-retest
reliability has been found to be .86 over a three-week
interval and the full-test split-half reliabilities range
from .91-.93. Discriminant and convergent validity
has been demonstrated.
2. The EATask (Empathic Accuracy) [32] is an empathy
measure, in which subjects are shown multimodal video
stimuli and are required to make continuous inferences
about a target’s specific thoughts and feelings, which are
later compared to the targets’ reported actual thoughts
Table 3 TRuSST Study primary and secondary outcome measures
Domain Outcome measure
Co-Primary Outcome
Measures
Social Cognition Penn Emotion Recognition Test (ER40)
Prosody Identification (PROID)
Penn Facial Memory Test (PFMT)
MSCEIT-managing emotions subscale
The Empathic Accuracy (EA)
Functional Capacity The UCSD Performance-based Skills Assessment
(UPSA-2)
Secondary Outcome
Measures
Symptom Severity Positive and Negative Syndrome Scale (PANSS)
Functioning Global Functioning Scale
Social Functioning Scale
The Specific Levels of Function (SLOF)
VRFCAT
Social Cognition The Awareness of Social Inference
Test (TASIT), Part 3
The Morphed Faces Task The Faux Pas Test
The Source Memory Test
The Ambiguous Intentions Hostility
Questionnaire (AIHQ)
Motivation Behavioral Inhibition/Behavioral
Activation Scale (BIS-BAS)
Temporal Experience of Pleasure Scale (TEPS)
Quality of Life The Quality of Life Scale (QLS)
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and feelings in order to compute an index of the
perceiver’s accuracy. Empathic accuracy has been
shown to demonstrate adequate test-retest
reliability (.72).
Functional Capacity Outcome Measure
The a priori co-primary functional measure will be the
functional capacity measure of The UCSD Performance-
based Skills Assessment (UPSA-2)[96].The UPSA is a
well-validated measure frequently used in cognitive and
SC training studies [68]; In addition, it measures func-
tional capacity, which is expected to be affected by social
cognitive change. The UPSA-2 is designed to assess
skills in five areas (Household Chores, Communication,
Finance, Transportation, and Planning Recreational Ac-
tivities) that reflect general abilities that are important
components of independent living. Test-retest reliabil-
ity ranged from .63-.80 over follow-up periods up to
36 months in patients with schizophrenia. Among pa-
tients, the UPSA performance correlated significantly
with severity of negative symptoms and of cognitive im-
pairment but not with that of positive or depressive
symptoms.
Secondary Outcome Measures
The following validated and normed assessments will be
used as secondary outcome measures in the study:
Clinical Status and Symptom Severity
We will use the PANSS (Positive and Negative Syndrome
Scale) [89] to assess clinical status and severity of symp-
toms. The PANSS is a clinically-administered exam used
for measuring symptom severity of patients with schizo-
phrenia of 30 different symptoms, divided into Positive,
Negative, and General Psychopathology scales. These
scales have been found by coefficient alpha, split-half
method, and test-retest reliability testing to be intern-
ally consistent and highly reliable [97].
Functioning
The following set of outcome measures will be used to
assess global and social functioning:
1. GFS (Global Functioning Scale)[98, 99] is a clinician-
administered questionnaire which is used to assess
general psychosocial functioning. It has two subscales:
role and social.
2. SFS (Social Functioning Scale)[100] is a self-report
questionnaire designed to assess social functioning
in individuals with schizophrenia. To be completed
by both the subject and a relative, the scale is made
up of 54 questions divided into seven sections. Results
from three samples show the SFS is reliable, valid,
sensitive and responsive to change.
3. SLOF (Specific Levels of Functioning)[101] is a
43-item scale designed to assess in detail an individual’s
basic living skills and level of independent functioning.
Item reliabilities are .62 in community programs and
0.42 in state hospital; internal consistency > =.91.
4. VRFCAT (Virtual Reality Functional Capacity
Assessment)[85] is a virtual reality measure
mimicking a real-life scenario of a shopping trip.
The test has several alternate forms and it records
number of errors and RT for task completion.
5. The QLS (Quality of Life Scale)[102] will be used as
a secondary outcome measure to assess quality of
life. QLS is a 16-item instrument used to measure
five conceptual domains of quality of life. It has low
to moderate correlations with physical health status
and disease measures; however, content validity
analysis indicates that the instrument measures
domains that diverse patient groups with chronic
illness define as quality of life.
Motivation
The following secondary outcome measures will be used
to assess motivation:
1. BIS/BAS (Behavioral Inhibition/Behavioral Activation
Scale)[103] is a 24-item self-report questionnaire
designed to assess the two general motivational
systems that underlie behavior and affect, i.e. sensitivity
to anticipated punishment or reward. Test-retest
correlations were found to range from .59-.69.
2. TEPS (Temporal Experience of Pleasure Scale)[104]
is a measure specifically designed to capture the
anticipatory and consummatory facets of pleasure.
The 10-item anticipatory pleasure scale and 8-item
consummatory pleasure scale were found to be
internally consistent, temporally stable and moderately,
positively correlated with each other.
Social Cognition
The following social cognition measures will be used as
secondary outcome measures, in addition to the primary
social cognitive outcome measures:
1. TASIT (The Awareness of Social Interaction
Test)[105], part 3. The TASIT is a social perception
test in which subjects watch scenes which involve
lie/sarcasm and are asked questions about them; We
will use the 3rd part of the test, the Social Interference
Enriched test. Test-retest reliability has been found to
range from .74-.88 and alternative forms reliability
ranges from .62-.83.
2. The Morphed Faces task [106] is a computerized
emotion perception task, in which participants are
presented with faces that are morphed between a
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neutral expression and an emotional expression:
happy, disgusted, angry, or fearful. All faces are
morphed between a neutral expression and either
20, 30, 40, 50, or 60 of the emotional expression,
and are created from 1 male, and 2 female targets,
resulting in a total of 60 face stimuli (3 targets, 5
levels of morph, 4 emotions).
3. The Faux Pas test [107] will be used as a Theory of
Mind (ToM) measure. The test is comprised of 20
short stories, incidents of faux pas (someone
mistakenly saying something they shouldn't have).
Stories are read to the individual, who is then asked
questions to determine whether or not they
recognized the faux pas.
4. The Source Memory Test [31] is a measure of
memory for the source of self-generated, and
experimenter-provided word items that shows
strong associations to social cognition[108]
5. AIHQ (The Ambiguous Intentions Hostility
Questionnaire)[109] is a measure of attributional
style, and specifically of hostile social-cognitive
biases comprised of a variety of negative situations
that differ in terms of intentionality. This measure
has demonstrated good levels of internal consistency
and inter-rater reliability, and is positively correlated
with paranoia and hostility but not correlated with
measures of psychosis proneness (convergent and
discriminant validity).
Randomization
Participants will be randomized after the last baseline
visit (V2) and before the planned program set-up visit
(V3), which is the first day of program use. All V0-V2
data for each participant must be fully monitored, with
all queries resolved, before randomization may take place.
Given the potential importance of cognitive abilities on
the response to social cognitive training, participants will
be stratified by gender, education (<13 years, >13 years)
and age (18–40 years, 41–65 years) and randomly
assigned to either treatment (SocialVille) or active con-
trol group at each site with an allocation ratio of 1:1.
We will employ a minimization method of adaptive strati-
fied randomization (referred to as the ‘platinum standard’
of randomization methods when stratification is required)
to minimize the imbalance between the number of partici-
pants in each group over these factors.
For this trial, we will use a secure randomization server
(Sealed Envelope) that implements the specified proced-
ure and an unblinded study member Site Coordinating
Center will issue a randomization assignment at the ap-
propriate time. This approach represents a best practice
approach to randomization, implementing an automated
centralized group assignment procedure with allocation
concealment, and effective separation of sequence gener-
ation and allocation concealment.
Blinding
Un-blinded Site Roles
At each site, Cognitive Remediation Coaches are un-blinded
in order to provide support for participants using their
assigned programs. They will be distinct from staff ad-
ministering and scoring assessments. Additionally, Site
Sub-Investigators authorized to register participants within
the TRuSST system will remain un-blinded and may not
participate in the assessment, evaluation, or follow-up
of study participants.
Blinded Site Roles
All site staff responsible for the administration and scor-
ing of participant assessments will remain blinded to
participant treatment. Site Principal Investigators will be
required to complete a Delegation of Authority Form
prior to the start of the study, indicating which activities
individual site research team members will be authorized
to complete. Site Principal Investigators will also remain
blinded.
Depending upon the extent to which they are respon-
sible for data collection and/or entry, Clinical Research
Coordinators may or may not remain un-blinded to par-
ticipant treatment. This will be clarified on a site-by-site
basis and will be noted on the Site Principal Investigator
Delegation of Authority Form.
To prevent un-blinding, the following safeguards will
be instituted at each site:
1. The treatment condition and the control condition
will be identified as “Treatment A” and “Treatment B”;
2. Participants will be reminded not to discuss details
related to treatment with psychometricians and/or
clinical evaluators during the informed consent
process as well as prior to initiation and at the
conclusion of each assessment visit;
3. Site personnel will be instructed to not discuss
details of either treatment arm during open
participant groups or forums;
4. Sites will be required to execute the protocol in a
manner that minimizes the possibility of accidental
un-blinding of psychometricians or clinical evaluators
(e.g. unintended viewing of treatment sessions);
5. Sites will be asked to post signage in appropriate
areas throughout the facility reminding staff and
participants to not discuss treatment details in open
locations.
At the end of the trial, psychometricians will be asked
questions designed to evaluate the integrity of the blinding
procedures employed throughout the trial.
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Description of Treatment Programs
Experimental Treatment Program (SocialVille)
The Experimental Treatment Program (SocialVille) is a
computerized social cognitive remediation program con-
sisting of a set of specific social cognitive exercises. To
use the experimental treatment program, a participant
opens a standard web browser on a broadband connected
computer and goes to the experimental treatment program
study web site. The participant then logs into the experi-
mental treatment program server (using a study provided
login that contains no personally identifiable information).
The participant completes 7 cognitive exercise blocks
scheduled for the day, and performs each exercise for
about 6 minutes (see Fig. 2). Participants perform tens
to hundreds of trials over the course of a session, with
auditory and visual feedback and rewards to indicate if
the trial was performed correctly or incorrectly. After
each session, the difficulty of the next session is up-
dated (e.g., more distractors in the response array) to
ensure that each participant is appropriately challenged.
Summary screens including game metrics (points, levels)
and exercise metrics (usage, progress) are shown to the
participant at the end of each session.
All usage and progress data are encrypted then transmit-
ted to a central server. In a research study such as this one,
no personally identifiable information is stored on the ser-
ver (including internet protocol addresses). On the server,
the data are available for review by the un-blinded Cogni-
tive Remediation Coach or Site Coordinator through a se-
cure web portal. Only data from participants at a particular
Site can be viewed by that Site’s staff. The Cognitive Re-
mediation Coach in particular will use the secure web por-
tal to regularly check on usage and progress of each active
participant to customize their weekly phone/in-person dis-
cussions to provide helpful guidance and coaching.
There are multiple social cognitive exercises in Social-
Ville, collectively targeting the five social cognitive domains
identified in the literature: affect perception, social cue per-
ception, theory of mind (ToM), self-referential style and
empathy (see Table 2 for a complete list of exercises). All
Fig. 2 Examples of SocialVille Training Exercises. a. The daily schedule consists of 7 exercises of 6 minutes each, for a total of 42 minutes. b. Match that
Feeling exercise example. In this exercise, participants are required to match the emotion depicted by the person in the target image to the emotion
of a different person from a group of faces. C. Face Facts exercise example. In this exercise, participants must remember the given facts associated with
a specific person
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exercises continuously adjust difficulty level to user per-
formance to maintain a 70-80% correct performance rate
using adaptive algorithms. The scheduling mechanism en-
sures that a participant progresses through the exercises in
a defined order, generally moving from more simple (e.g.,
easy to discriminate stimulus types, less response options)
exercises to more complex (e.g., greater rule complexity,
greater similarity between stimuli, etc.) exercises over the
course of the 8–12 weeks experience.
Active Control Program (commercially-available computer
games)
The active control group will use conventional, pro-
gressive computer games. The 13 computer games (see
Table 3 for full list) have been embedded in the training
portal; this should greatly facilitate administration, and
will allow maintenance of the double-blind procedure
of both staff and participants, while controlling for pla-
cebo effects, time spent on computer, exposure to study
staff, and non-specific effects from attended, rewarded ex-
posure to multi-media stimulation.
This type of control is suitable for an efficacy trial, and
is designed to approximate the same level of challenge
as in the active training group. Moreover, it is the only
possible control in the absence of a standardized social
cognitive treatment in schizophrenia: a social skills group
control would not control for number of clinic visits,
interaction with study staff and other patients, and in
addition it is unclear which of the potential group treat-
ments should be chosen; A computerized social cognitive
treatment is not conventionally employed, and available
experimental ones critically differ from the SocialVille
intervention in scope (targeting only a single SC domain)
hence may not serve as a true control.
The active control intervention is administered in exactly
the same way as the treatment intervention: it is browser-
playable (from any browser) and login and password-
protected. We randomly select a subset of 7 games sub-
jects play on every session, for 6 minutes each, to equate
for the time spent by the treatment group participants
(see Fig. 3). The number, availability, and time spent on
each game is managed by the same server which man-
ages the treatment group exercises, hence experience is
matched between the two groups. We will use games that
have been shown to provide face-valid cognitive stimula-
tion and that are rated E (for everyone) by the Entertain-
ment Software Rating Board (ESRB).
The Cognitive Remediation Coach in particular will use
the secure web portal to regularly check on usage of each
active participant to customize their weekly phone/email
discussions to provide helpful guidance and coaching.
This ensures that the experimental treatment and active
control groups are matched for social contact and en-
couragement from the Cognitive Remediation Coach.
Power Calculation for Sample Size
With the aim of having 128 participants complete the
study, we have statistically powered it to detect a between-
groups Cohen’s d effect size of 0.50 on an outcome meas-
ure, calculated as the between-group difference in the
treatment effect means (post-assessment score minus pre-
assessment score) divided by the pooled standard devi-
ation of the observed test-retest reliability. This effect size
translates, for example, in an improvement of 5.8 points
(on an IQ-like index score) within the treatment group
versus an improvement of 1.0 point within the active
control group, with both groups showing a variance of
10 points (2/3 of a standard deviation, as observed in
other composite cognitive performance data) from pre-
assessment to post-assessment. The results of our feasi-
bility study [80] allowed us to derive training group
effect sizes; these ranged from 0.45-1.1 on the SocialVille
measures, from 0.53-0.77 for the social cognitive measures
and from 0.4-0.67 for the generalization and functional
measures. A recent study conducted by our study collab-
orator, Prof. Vinogradov [61] employed computerized so-
cial cognitive training and found effect sizes of 0.53 on the
MSCEIT [94] perceiving emotions total subscale. Further-
more, a recent meta-analysis conducted on social cogni-
tive training interventions in schizophrenia [68] found
moderate to large effect sizes on facial affect recognition
(Cohen’s d between 0.71-1.01) and small to moderate ef-
fect sizes on ToM (0.46). Effect size for total symptoms
was found to be moderate to large (0.68). We therefore
believe this is a reasonable estimate of the plausible effect
size in the suggested trial, and that documentation of a 0.5
between-groups effect size in this trial would provide rea-
sonable support for clinical benefit in this population.
Data Analysis
For the main analysis of this study (evaluating the efficacy
of SocialVille as a treatment for social cognition deficits)
we will define an Intent-To-Treat (ITT) population that
includes all participants who have been randomized to ei-
ther group. We will compare treatment and active control
groups in the ITT population to determine if any differ-
ences in baseline demographic, characterization, outcomes
variables, or total program use time remain after the
randomization process.
We will test the following hypotheses of the primary
outcomes, in addition to exploratory analyses: (1) Experi-
mental treatment versus active control improves social
cognition, and (2) Experimental treatment versus active
control improves functional capacity. In addition, we will
test the following hypotheses of the secondary outcomes:
(1) Experimental treatment versus active control improves
symptom severity; (2) Experimental treatment versus ac-
tive control improves functioning; (3) Experimental treat-
ment versus active control improves social cognition; (4)
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Experimental treatment versus active control improves
motivation, and (5) Experimental treatment versus active
control improves quality of life.
To examine each hypothesis, we will examine the data
from each outcome measure(s) associated with the Primary
or Secondary outcomes using a linear mixed-effects model
with group and time as fixed factors, site as a random fac-
tor, and additional factors/covariates as required if there
are trends towards significant baseline differences (p < 0.1)
in the treatment and active control groups. Missing data
will be handled with an iterative maximum likelihood pro-
cedure to optimally estimate model parameters. The key
value for significance will be the group-by-time interaction
term. This modeling will be conducted with a Type I error
set at 0.025 for each model.
In addition, to identify variables that predict treatment
success in the SocialVille group, we will use an individual
differences approach [80] and test for associations be-
tween not only outcome variables and pre-test scores (raw
and composite), but also between outcome variables and
Fig. 3 Examples of Active Control (AC) Program Training Exercises. a. This daily schedule for the AC program is the same as the SocialVille program,
with 7 exercises presented per day for 6 minutes each. b. Some exercises include Tri Peaks Solitaire (3-deck solitaire), War Ship (Battleship), and Bricks
Breaking Hex (remove tiles of the same color)
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improvements in aspects of the training tasks. This will
help us determine if specific types of patients benefit from
training more than others as well as if particular improve-
ment patterns on training (i.e., training strategies) are
predictive of successful outcomes. These analyses will
be evaluated after correcting for multiple comparisons
(i.e., Bonferroni).
Finally, following the main analyses, we will construct
two separate composites, of low-level and high-level SC
assessments, respectively, and test the effects of training
on each of these composites using a linear mixed-effects
model. We will further examine correlations between
magnitude of change on each of the constructs and %
improvement on SocialVille exercises.
Discussion
Despite the functional significance of social cognition to
everyday function, there is currently no effective and
widely-adopted treatment approach for the extremely
debilitating social cognition deficits seen in schizophre-
nia. The current TRuSST protocol shall help determine
whether SocialVille is an effective treatment method for
social cognition deficits in schizophrenia, promoting social
and functional benefits that could potentially improve
the quality of life of afflicted individuals and their family
members. The fact that SocialVille is a highly-scalable
intervention, deployed to any number of individuals at
minimal cost and does not require additional clinical
training, strengthens the notion that a successful TRuSST
trial could result in the rapid utilization of SocialVille in
schizophrenia treatment, creating a new and improved
standard of care for this condition.
Strengths
A major strength of the study is that it deploys simple
interventions that can be administered completely re-
motely, with minimal remote clinical monitoring, planned
for a phone call or email once/week to check in on partici-
pants and see if they encounter any difficulty completing
their training. Deploying interventions remotely and
saving the multiple clinical visits should potentially facili-
tate compliance with study requirements, and allow to
mimic real-life deployment of the training program.
In addition, many previous studies and clinical trials
testing social cognitive benefits in schizophrenia lacked
statistical power due to relatively small sample sizes (e.g.
[66, 70, 110–113]) or the lack of a control intervention
(e.g. [84, 114, 115]). The TRuSST sample size, of 128
individuals, should power it to detect appropriate effect
sizes. In fact, TRuSST is one of largest trials, to the best
of our knowledge that were conducted in this field of
social cognition in schizophrenia. The fact that it is a
double-blind study further strengthens the credibility of
its potential outcomes, which cannot be attributed to
placebo effects or interaction with study staff.
Finally, the study employs a very large battery of out-
come measures, encompassing the domains of social cog-
nition, social functioning, quality of life and functional
capacity. Specifically, the study employs some novel as-
sessments as secondary outcome measures (e.g. VRFCAT
[83]), and should thus help validate and norm these novel
measures for schizophrenia, on the path of making them
the new gold standard in the field.
Weaknesses
Our protocol has some potential limitations. Due to the
relatively long duration and multiple components of our
study, attrition rates may pose a potential limitation, mak-
ing it difficult to reach our recruitment goal. Furthermore,
one of the common symptoms of schizophrenia is a lack
of motivation [116, 117], which could prevent timely
completions of the self-initiated training program. With
a standardized protocol, frequent check-ins, and regular
feedback from our research assistants, we aim to limit
drop-out rate and motivate individuals to continue with
training through completion.
Trial Status
The trial is currently in the recruitment phase.
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